Prosecution Insights
Last updated: October 02, 2026

Examiner: BERRIOS, JENNIFER A

Tech Center 1600 • Art Units: 1613 1619 1655

This examiner grants 37% of resolved cases

Analysis

Jennifer A Berrios is an examiner in Tech Center 1600 and Art Unit 1613 with 815 resolved cases. Her allowance rate is 37.1 percent, and the median days to allowance is 1318. These metrics provide a statistical basis for observations within the 1600 tech center. The 1318-day median is a benchmark for the duration of the 815 cases she has handled.

The interview lift of 49.7 percent is a significant figure compared to the 37.1 percent allowance rate. This suggests that interviews are an effective tool for improving the probability of a grant. For the 815 cases resolved, the 1318-day median pendency highlights the importance of using the 49.7 percent lift to reach a resolution. The contrast between the allowance rate and the lift is a key feature of her profile. Practitioners should consider an interview given this 49.7 percent lift. The 1318-day median pendency remains a factor for any applicant.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

37.0%
Allow Rate
-23.0% vs TC avg
884
Total Applications
+49.8%
Interview Lift
1319
Avg Prosecution Days
Based on 816 resolved cases, 2023–2026

Rejection Statute Breakdown

1.4%
§101 Eligibility
8.3%
§102 Novelty
52.2%
§103 Obviousness
22.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17549307 OCULAR INSERT CONTAINING A GLUCOCORTICOID Final Rejection Ocular Therapeutix, Inc.
18852384 VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS Non-Final OA The Regents of the University of California
18906424 Emulsions Containing a UV-Absorbing System Including Physical UV-Attenuating Material, Surfactant, and Thickener Non-Final OA L'OREAL
18719728 COMPOSITION FOR LIGHTENING KERATIN FIBRES AND PROCESS FOR LIGHTENING KERATIN FIBRES USING THIS COMPOSITION Non-Final OA L'OREAL
18355526 METHODS AND COMPOSITIONS FOR TREATING OXIDATIVELY BLEACHED OR COLORED HAIR Non-Final OA L'OREAL
18355480 METHODS FOR SMOOTHING HAIR Non-Final OA L'OREAL
18355455 HAIR TREATMENT COMPOSITION AND METHODS FOR SMOOTHING HAIR Non-Final OA L'Oreal
18343506 HAIR TREATMENT COMPOSITION COMPRISING KETAL/ACETAL OF GLYCERIN Non-Final OA L'OREAL
18343570 ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER Non-Final OA L'OREAL
18268098 AEROSOL DEVICE CONTAINING A COMPOSITION COMPRISING A SOLID FATTY ALCOHOL, A MONOALCOHOL AND A COMPRESSED GAS Final Rejection L'Oreal
18001973 KIT AND COSMETIC PROCESS USING MICRONEEDLE SHEET Final Rejection L'OREAL
17907481 COSMETIC COMPOSITION FOR SKIN CARE Non-Final OA L'OREAL
17618204 COMPOSITION COMPRISING BIOSURFACTANT AND CARBOXYBETAINE POLYMER Final Rejection L'OREAL
17513988 WATER-IN-OIL EMULSIONS INCLUDING SURFACTANT, ACRYLIC POLYMER AND ORGANOSILOXANE Final Rejection L'OREAL
16617063 COMPOSITION FOR CONDITIONING HAIR Non-Final OA L'OREAL
18846127 COSMETIC Non-Final OA SHISEIDO COMPANY, LTD.
18275563 COSMETIC PREPARATION Final Rejection SHISEIDO COMPANY, LTD.
17512381 GINSENG POWDER, COSMETIC COMPOSITION COMPRISING SAME AND PREPARATION METHOD THEREOF Final Rejection AMOREPACIFIC CORPORATION
19079754 WHIPPED FORMULATIONS WITH DESIRED SENSORY IMPACT Non-Final OA BEIERSDORF AG
18258084 A SYNERGISTIC PERFUMING COMPOSITION Final Rejection Firmenich SA
17573055 SKIN CARE COMPOSITIONS COMPRISING A TERPOLYMER, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF Non-Final OA ISP INVESTMENTS LLC
17615894 A COOLING PREPARATION Final Rejection SYMRISE AG
17604183 SELF-EMULSIFYING DRUG DELIVERY SYSTEMS FOR DELIVERY OF LIPOPHILIC COMPOUNDS Non-Final OA Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
18264080 HAIR CONDITIONER FORMULATION Final Rejection Union Carbide Corporation
18263980 FORMULATION FOR THE CARE OF DAMAGED HAIR Final Rejection Union Carbide Corporation
17433819 COSMETIC COMPOSITION BASED ON A PLANT PRODUCT Non-Final OA FREEDGE SAS
17309546 COLONIC DRUG DELIVERY FORMULATION Non-Final OA Tillotts Pharma AG

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month